Ardent Health, Inc. (ARDT)
| Market Cap | 1.48B -20.1% |
| Revenue (ttm) | 6.41B +3.3% |
| Net Income | 78.23M -69.3% |
| EPS | 0.55 -69.6% |
| Shares Out | 141.05M |
| PE Ratio | 18.98 |
| Forward PE | 9.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 237,647 |
| Open | 10.58 |
| Previous Close | 10.62 |
| Day's Range | 10.40 - 10.74 |
| 52-Week Range | 7.71 - 15.48 |
| Beta | 0.70 |
| Analysts | Buy |
| Price Target | 12.68 (+20.99%) |
| Earnings Date | Aug 4, 2026 |
About ARDT
Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States. The company offers general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services within inpatient and ambulatory care settings. It also operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers, urgent care centers, free... [Read more]
Financial Performance
In 2025, Ardent Health's revenue was $6.32 billion, an increase of 6.01% compared to the previous year's $5.97 billion. Earnings were $135.81 million, a decrease of -35.43%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ARDT stock is "Buy." The 12-month stock price target is $12.68, which is an increase of 20.99% from the latest price.
News
Oklahoma Heart Institute brings new cardiovascular trials, tech to patients
Oklahoma Heart Institute, OHI, part of Hillcrest HealthCare System and Ardent Health (ARDT) is now the only site in Oklahoma and the surrounding region participating in several leading national cardio...
Oklahoma Heart Institute Brings New National Cardiovascular Trials and Technologies to Patients Across the Region
BRENTWOOD, Tenn. & TULSA, Okla.--(BUSINESS WIRE)--Oklahoma Heart Institute (OHI), part of Hillcrest HealthCare System and Ardent Health (NYSE: ARDT), is now the only site in Oklahoma and the surroundi...
Ardent Health price target raised to $10 from $9 at BofA
BofA raised the firm’s price target on Ardent Health (ARDT) to $10 from $9 and keeps an Underperform rating on the shares. July data points better than Q2 for foot…
Ardent Health price target raised to $13 from $11 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Ardent Health (ARDT) to $13 from $11 and keeps a Neutral rating on the shares.
Ardent Health price target raised to $13 from $12 at Truist
Truist raised the firm’s price target on Ardent Health (ARDT) to $13 from $12 and keeps a Buy rating on the shares.
Ardent Health price target raised to $13 from $12 at Mizuho
Mizuho raised the firm’s price target on Ardent Health (ARDT) to $13 from $12 and keeps an Outperform rating on the shares.
Ardent Health price target raised to $14 from $13 at Guggenheim
Guggenheim raised the firm’s price target on Ardent Health (ARDT) to $14 from $13 and keeps a Buy rating on the shares, citing higher EBITDA estimates following the company’s Q2…
Ardent Health Earnings Call Transcript: Q2 2026
Q2 2026 saw revenue of $1.62B and adjusted EBITDA of $115M, with volumes rebounding in June after a weak April-May. Cost controls and a key payer contract offset volume headwinds, supporting reaffirmed full-year guidance and a raised IMPACT savings target.
Ardent Health Earnings release: Q2 2026
Ardent Health released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Ardent Health Slides: Q2 2026
Ardent Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Ardent Health Quarterly report: Q2 2026
Ardent Health has published its Q2 2026 quarterly earnings report on August 5, 2026.
Ardent Health reports Q2 EPS 12c, consensus 19c
Reports Q2 revenue $1.62B, consensus $1.59B. “As I transition to the CEO role, I’m looking forward to building on the momentum of key initiatives launched during my COO tenure as…
Ardent Health cuts FY26 EPS view to 78c-$1.15 from 90c-$1.27, consensus $1.28
Backs FY26 revenue view $6.4B-$6.7B, consensus $6.44B.
Ardent Health Reports Second Quarter 2026 Results
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health, Inc. (NYSE: ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today a...
Ardent Health surpasses 1M patient encounters supported by ambient AI
Ardent Health (ARDT) announced that its physicians and advanced practice providers have surpassed 1M patient encounters supported by Ambience Healthcare’s ambient AI platform, “marking a significant m...
Ardent Health surpasses 1 million patient encounters supported by ambient AI
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT) today announced that its physicians and advanced practice providers have surpassed 1 million patient encounters supported by Ambience Heal...
Ardent Health Announces Second Quarter 2026 Results Conference Call and Webcast Date
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its second qu...
Ardent Health price target lowered to $9 from $9.50 at BofA
BofA lowered the firm’s price target on Ardent Health (ARDT) to $9 from $9.50 and keeps an Underperform rating on the shares. The firm cut its price targets for hospitals…
Ardent Health price target lowered to $12 from $13 at Truist
Truist lowered the firm’s price target on Ardent Health (ARDT) to $12 from $13 and keeps a Buy rating on the shares as part of a broader research note previewing…
Ardent Health price target lowered to $12 from $13 at RBC Capital
RBC Capital analyst Ben Hendrix lowered the firm’s price target on Ardent Health (ARDT) to $12 from $13 and keeps an Outperform rating on the shares as part of a…
Ardent Health Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
A proactive leadership transition aims to drive operational rigor and margin expansion, supported by the IMPACT Program targeting $55 million in savings. Despite industry-wide volume softness and reimbursement headwinds, the organization is investing in ambulatory growth, AI initiatives, and disciplined M&A, while maintaining a strong financial outlook.
Ardent Health price target lowered to $9 from $10 at BofA
BofA lowered the firm’s price target on Ardent Health (ARDT) to $9 from $10 and keeps an Underperform rating on the shares. The firm is lowering its price targets for…
Ardent Health to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that the Company will participat...
Morgan Stanley says Ardent softer volume commentary adds to list of concerns
Morgan Stanley notes after Ardent Health (ARDT) announced the appointment of COO Dave Caspers as President and CEO, effective immediately, that the CFO and investor relations team commented that the…
Ardent Health names Dave Caspers as CEO
Ardent Health (ARDT) announced that Dave Caspers has been appointed President and Chief Executive Officer, effective immediately. Mr. Caspers, who previously served as Chief Operating Officer, succeed...